Roche received inconclusive test results, medication against ulcerative colitis atropisomers (etrolizumab) in patients with moderately severe and severe form of the disease. About it writes Reuters.
The company explained that in both studies, the effect of atropisomers as a maintenance therapy. As evidenced by the obtained data, the drug use has no statistically significant effectiveness in terms of achievement of remission compared to placebo.
Despite the setback for this indication Roche intends to continue research atropisomers among patients with Crohn’s disease.